AAN: Once-Daily Eslicarbazepine Helps Prevent Seizures

Share this content:
AAN: Once-Daily Eslicarbazepine Helps Prevent Seizures
AAN: Once-Daily Eslicarbazepine Helps Prevent Seizures

FRIDAY, April 15, 2016 (HealthDay News) -- Once-daily eslicarbazepine acetate (Aptiom) may control seizures just as well as twice-daily carbamazepine (Tegretol, Carbatrol), according to research scheduled to be presented at the annual meeting of the American Academy of Neurology, held from April 15 to 21 in Vancouver, Canada.

Elinor Ben-Menachem, M.D., of Gothenburg University in Sweden, and colleagues compared once-daily eslicarbazepine acetate to twice-daily carbamazepine in 815 patients newly diagnosed with partial seizures.

After six months, 71 percent of those taking eslicarbazepine and 76 percent of those taking carbamazepine were seizure-free. After one year, 65 percent of those taking eslicarbazepine and 70 percent of those taking carbamazepine were seizure-free.

"Seizure control is crucial. A once-a-day drug may help people stick to their medication schedule," Ben-Menachem said in a news release from the American Academy of Neurology. "Memory issues, fatigue or a complicated medication schedule can all interfere with a person taking their seizure-control medications on a regular basis," she added, "so having a once-daily option for patients, especially when they are newly diagnosed and still learning to manage the disease, may be beneficial."

The study was funded by Portuguese drug maker BIAL-Portela & Ca.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths